Bifogade filer
Kurs & Likviditet
Prenumeration
Kalender
2024-10-31 | Kvartalsrapport 2024-Q3 |
2024-08-29 | Kvartalsrapport 2024-Q2 |
2024-05-06 | Ordinarie utdelning BINV 0.00 SEK |
2024-05-03 | Årsstämma 2024 |
2024-04-24 | Kvartalsrapport 2024-Q1 |
2024-02-22 | Bokslutskommuniké 2023 |
2023-10-26 | Kvartalsrapport 2023-Q3 |
2023-08-30 | Kvartalsrapport 2023-Q2 |
2023-04-28 | Ordinarie utdelning BINV 0.00 SEK |
2023-04-27 | Årsstämma 2023 |
2023-04-26 | Kvartalsrapport 2023-Q1 |
2023-02-22 | Bokslutskommuniké 2022 |
2022-10-27 | Kvartalsrapport 2022-Q3 |
2022-08-25 | Kvartalsrapport 2022-Q2 |
2022-07-12 | Extra Bolagsstämma 2022 |
2022-04-29 | Ordinarie utdelning BINV 0.00 SEK |
2022-04-28 | Årsstämma 2022 |
2022-04-27 | Kvartalsrapport 2022-Q1 |
2022-02-23 | Bokslutskommuniké 2021 |
2021-10-28 | Kvartalsrapport 2021-Q3 |
2021-08-26 | Kvartalsrapport 2021-Q2 |
2021-04-30 | Ordinarie utdelning BINV 0.00 SEK |
2021-04-29 | Årsstämma 2021 |
2021-04-28 | Kvartalsrapport 2021-Q1 |
2021-03-23 | Extra Bolagsstämma 2021 |
2021-02-23 | Bokslutskommuniké 2020 |
2020-12-14 | Split BINV 25:1 |
2020-11-27 | Extra Bolagsstämma 2020 |
2020-10-29 | Kvartalsrapport 2020-Q3 |
2020-08-27 | Kvartalsrapport 2020-Q2 |
2020-05-29 | Ordinarie utdelning BINV 0.00 SEK |
2020-05-28 | Årsstämma 2020 |
2020-04-28 | Kvartalsrapport 2020-Q1 |
2020-02-27 | Bokslutskommuniké 2019 |
2019-10-24 | Kvartalsrapport 2019-Q3 |
2019-08-22 | Kvartalsrapport 2019-Q2 |
2019-04-26 | Ordinarie utdelning BINV 0.00 SEK |
2019-04-25 | Kvartalsrapport 2019-Q1 |
2019-04-25 | Årsstämma 2019 |
2019-03-20 | Extra Bolagsstämma 2019 |
2019-02-25 | Bokslutskommuniké 2018 |
2018-10-24 | Kvartalsrapport 2018-Q3 |
2018-07-24 | Kvartalsrapport 2018-Q2 |
2018-04-25 | Ordinarie utdelning BINV 0.00 SEK |
2018-04-24 | Kvartalsrapport 2018-Q1 |
2018-04-24 | Årsstämma 2018 |
2018-01-30 | Bokslutskommuniké 2017 |
2017-10-26 | Kvartalsrapport 2017-Q3 |
2017-07-26 | Kvartalsrapport 2017-Q2 |
2017-05-18 | Ordinarie utdelning BINV 0.00 SEK |
2017-05-17 | Kvartalsrapport 2017-Q1 |
2017-05-17 | Årsstämma 2017 |
2017-02-15 | Bokslutskommuniké 2016 |
2017-01-24 | Extra Bolagsstämma 2017 |
2016-10-25 | Kvartalsrapport 2016-Q3 |
2016-07-26 | Kvartalsrapport 2016-Q2 |
2016-05-13 | Ordinarie utdelning BINV 0.00 SEK |
2016-05-12 | Årsstämma 2016 |
2016-04-26 | Kvartalsrapport 2016-Q1 |
2016-03-18 | Extra Bolagsstämma 2016 |
2016-02-17 | Bokslutskommuniké 2015 |
2015-10-22 | Kvartalsrapport 2015-Q3 |
2015-07-22 | Kvartalsrapport 2015-Q2 |
2015-04-23 | Ordinarie utdelning BINV 0.00 SEK |
2015-04-22 | Årsstämma 2015 |
2015-04-22 | Kvartalsrapport 2015-Q1 |
2015-02-18 | Bokslutskommuniké 2014 |
2014-10-23 | Kvartalsrapport 2014-Q3 |
2014-07-24 | Kvartalsrapport 2014-Q2 |
2014-05-06 | Kvartalsrapport 2014-Q1 |
2014-04-25 | Ordinarie utdelning BINV 0.00 SEK |
2014-04-24 | Årsstämma 2014 |
2014-03-19 | Extra Bolagsstämma 2014 |
2014-02-20 | Bokslutskommuniké 2013 |
2013-10-24 | Kvartalsrapport 2013-Q3 |
2013-07-25 | Kvartalsrapport 2013-Q2 |
2013-06-19 | Extra Bolagsstämma 2013 |
2013-04-26 | Ordinarie utdelning BINV 0.00 SEK |
2013-04-25 | Kvartalsrapport 2013-Q1 |
2013-04-25 | Årsstämma 2013 |
2013-02-21 | Bokslutskommuniké 2012 |
2012-10-18 | Kvartalsrapport 2012-Q3 |
2012-09-28 | Kapitalmarknadsdag 2012 |
2012-07-19 | Kvartalsrapport 2012-Q2 |
2012-04-19 | Kvartalsrapport 2012-Q1 |
2012-03-27 | Ordinarie utdelning BINV 0.00 SEK |
2012-03-26 | Årsstämma 2012 |
2012-03-09 | Extra Bolagsstämma 2012 |
2012-02-09 | Bokslutskommuniké 2011 |
2011-11-08 | Kapitalmarknadsdag 2011 |
2011-10-13 | Kvartalsrapport 2011-Q3 |
2011-07-14 | Kvartalsrapport 2011-Q2 |
2011-04-14 | Kvartalsrapport 2011-Q1 |
2011-03-25 | Ordinarie utdelning BINV 0.00 SEK |
2011-03-24 | Årsstämma 2011 |
2011-02-10 | Bokslutskommuniké 2010 |
2010-10-14 | Kvartalsrapport 2010-Q3 |
2010-07-14 | Kvartalsrapport 2010-Q2 |
2010-04-21 | Ordinarie utdelning BINV 0.00 SEK |
2010-04-20 | Årsstämma 2010 |
2010-04-15 | Kvartalsrapport 2010-Q1 |
2010-02-17 | Bokslutskommuniké 2009 |
2009-10-15 | Kvartalsrapport 2009-Q3 |
2009-07-15 | Kvartalsrapport 2009-Q2 |
2009-04-22 | Ordinarie utdelning BINV 0.00 SEK |
2009-04-21 | Årsstämma 1 |
2009-04-16 | Kvartalsrapport 2009-Q1 |
Beskrivning
Land | Sverige |
---|---|
Lista | Mid Cap Stockholm |
Sektor | Hälsovård |
Industri | Bioteknik |
Lund, Sweden – November 25, 2021 – The members of the Nomination Committee for BioInvent International AB:s (publ) (“BioInvent”) Annual General Meeting in 2022 have now been appointed.
The following representatives of BioInvent International AB’s shareholders will be members of the Nomination Committee for the Annual General Meeting 2022:
- Laura Feinleib, appointed by Redmile Group, LLC
- Erik Esveld, appointed by van Herk Investments B.V.
- Vincent Ossipow, appointed by Omega Funds, LP
- Leonard Kruimer, Chairman of the Board
The Nomination Committee shall prepare proposals for the Annual General Meeting in 2022 regarding Chairman of the General Meeting, Chairman of the Board and other Board members, board remuneration shared among the Chairman and other Board members, possible compensation for committee work, and election of auditors and auditor's fees.
The Annual General Meeting will be held on April 28, 2022 in Lund, Sweden.
Proposals to the Nomination Committee can be sent to Stefan Ericsson, by mail: BioInvent International AB (publ).), SE-223 70 Lund or telephone: +46 (0)46-46 286 85 50 in good time before March 10, 2022
For further information, please contact:
Cecilia Hofvander
Senior Director Investor Relations
Tel: +46 46 286 85 50
Email. cecilia.hofvander@bioinvent.com
BioInvent International AB (publ)
Co. Reg. No. Org nr: 556537-7263
Visiting address: Ideongatan 1
Mailing address: 223 70 LUND
Phone: +46 (0)46 286 85 50
www.bioinvent.com
About BioInvent
BioInvent International AB (Nasdaq Stockholm: BINV) is a clinical-stage biotech company that discovers and develops novel and first-in-class immuno-modulatory antibodies for cancer therapy, with currently three drug candidates in four ongoing clinical programs in Phase 1/2 trials for the treatment of hematological cancer and solid tumors, respectively. The Company’s validated, proprietary F.I.R.S.T™ technology platform simultaneously identifies both targets and the antibodies that bind to them, generating many promising new drug candidates to fuel the Company’s own clinical development pipeline or for additional licensing and partnering.
The Company generates revenues from research collaborations and license agreements with multiple top-tier pharmaceutical companies, as well as from producing antibodies for third parties in the Company’s fully integrated manufacturing unit. More information is available at www.bioinvent.com. Follow us on Twitter: @BioInvent.